Stephen P. Mulligan - Concepedia

Author

Stephen P. Mulligan

Also Known As

J Mulhern, J. Mok, Marek Trneny, S Mulligan, S P Mulligan, S. Mulligan, S. P. MULLIGAN, S. P. Mulligan, S.P. Mulligan, Sarah Mulligan

259

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

Royal North Shore Hospital The University of Sydney Peter MacCallum Cancer Centre Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

About

Stephen P. Mulligan is an author at Royal North Shore Hospital specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	32	2.2K
2	Health Sciences	9	9	653
3	Applied Physiology	2	2	27
4	Biochemistry	2	2	29
5	Natural Sciences	1	1	131

Stephen P. Mulligan

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd, Jennifer R. Brown, Susan O’Brien, New England Journal of Medicine	2014	1.6K
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2016	783
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Talha Munir, Jennifer R. Brown, Susan O’Brien, American Journal of Hematology	2019	451
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study Constantine S. Tam, Stephen Opat, Shirley D’Sa, Blood	2020	432
Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Larissa Belov, O de la Vega, Cristobal G. dos Remedios, PubMed ImmunologyPathologyImmunophenotypingImmunotherapyHematological Malignancy	2001	318
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Journal of Clinical Oncology	2018	305
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab John C. Byrd, Peter Hillmen, Susan O’Brien, Blood	2019	238
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study Andy C. Rawstron, Claudia Fazi, Andreas Agathangelidis, Leukemia	2015	235
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL Jennifer R. Brown, Peter Hillmen, Stephen J. O’Brien, Leukemia	2017	234
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project Andy C. Rawstron, Karl‐Anton Kreuzer, Asha Soosapilla, Cytometry Part B Clinical Cytometry	2017	192

Page 1